Infiltration of T Cells into a Three-Dimensional Psoriatic Skin Model Mimics Pathological Key Features.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
03 Apr 2019
Historique:
received: 05 03 2019
revised: 29 03 2019
accepted: 01 04 2019
entrez: 17 4 2019
pubmed: 17 4 2019
medline: 31 7 2019
Statut: epublish

Résumé

Psoriasis is an autoimmune chronic dermatosis that is T cell-mediated, characterized by epidermal thickening, aberrant epidermal differentiation and inflammatory infiltrates, with a dominant Th1 and Th17 profile. Additional in vitro models are required to study the complex interactions between activated T cells and skin cells, and to develop new, more effective treatments. We have therefore sought to model this psoriatic inflammation by the generation of tissue-engineered immunocompetent tissues, and we have investigated the response of activated T-cell infiltration in models produced with lesional psoriatic skin cells on major hallmarks of psoriasis. The immunocompetent lesional skin model displayed a delayed onset of epidermal differentiation, an hyperproliferation of the basal keratinocytes, a drastic increase in the secretion of proinflammatory cytokines, and a disturbed expression of key transcription factors, as observed in lesional plaques, suggesting a crucial importance of combining the pathological phenotype of cutaneous cells to T cells in order to generate a relevant model for psoriasis. Finally, we found this skin model to be responsive to methotrexate treatment, making it a valuable tool for drug development.

Identifiants

pubmed: 30987186
pii: ijms20071670
doi: 10.3390/ijms20071670
pmc: PMC6479293
pii:
doi:

Substances chimiques

Inflammation Mediators 0
Methotrexate YL5FZ2Y5U1

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Canadian Institutes of Health Research
ID : MOP-311262
Pays : Canada

Références

J Am Acad Dermatol. 2003 Jun;48(6):829-35
pubmed: 12789171
J Invest Dermatol. 1992 Jul;99(1):27-34
pubmed: 1351505
J Invest Dermatol. 1992 Jun;98(6):902-10
pubmed: 1375620
J Dermatol Sci. 1992 Jul;4(1):18-25
pubmed: 1390454
N Engl J Med. 2003 Nov 20;349(21):2014-22
pubmed: 14627786
J Exp Med. 2004 Mar 1;199(5):731-6
pubmed: 14981113
Trends Immunol. 2004 Jun;25(6):295-305
pubmed: 15145319
J Dermatol. 2004 Apr;31(4):271-6
pubmed: 15187321
J Clin Invest. 2004 Jun;113(12):1664-75
pubmed: 15199399
Curr Opin Rheumatol. 2004 Jul;16(4):331-7
pubmed: 15201593
N Engl J Med. 2005 May 5;352(18):1899-912
pubmed: 15872205
J Exp Med. 2005 Jul 4;202(1):135-43
pubmed: 15998792
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S67-80
pubmed: 16488332
Br J Dermatol. 2006 Nov;155(5):876-82
pubmed: 17034513
Arch Dermatol Res. 1991;283(7):465-71
pubmed: 1724897
Clin Exp Immunol. 2007 Dec;150(3):407-15
pubmed: 17900301
J Invest Dermatol. 2008 May;128(5):1207-11
pubmed: 18200064
J Invest Dermatol. 2009 Jan;129(1):79-88
pubmed: 18633443
Am J Pathol. 2008 Sep;173(3):815-23
pubmed: 18669614
J Dermatol Sci. 2009 Jan;53(1):19-25
pubmed: 18783923
J Exp Med. 2009 Jan 16;206(1):249-58
pubmed: 19114666
Nat Med. 2009 Sep;15(9):1013-5
pubmed: 19684581
Arch Dermatol Res. 2010 Sep;302(7):499-505
pubmed: 20148256
Curr Opin Immunol. 2010 Apr;22(2):223-30
pubmed: 20207527
J Invest Dermatol. 2010 Oct;130(10):2412-22
pubmed: 20555352
Am J Pathol. 2010 Dec;177(6):3112-24
pubmed: 20971736
Tissue Eng Part A. 2011 Jul;17(13-14):1859-68
pubmed: 21417679
J Allergy Clin Immunol. 2011 Sep;128(3):574-82.e1-12
pubmed: 21704361
J Invest Dermatol. 2011 Dec;131(12):2401-8
pubmed: 21796151
J Dermatol Sci. 1990 Nov;1(6):441-6
pubmed: 2288899
Br J Dermatol. 2013 Feb;168(2):302-10
pubmed: 23013371
Curr Opin Immunol. 2013 Apr;25(2):214-21
pubmed: 23298609
J Invest Dermatol. 2013 Oct;133(10):2362-2371
pubmed: 23594598
J Invest Dermatol. 2014 Mar;134(3):719-727
pubmed: 24121402
J Immunol. 2014 Apr 1;192(7):3111-20
pubmed: 24610014
Nat Rev Immunol. 2014 Nov;14(11):768-74
pubmed: 25257362
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8046-51
pubmed: 26080440
Eur J Immunol. 2015 Nov;45(11):3022-33
pubmed: 26332438
Regen Med. 2016 Sep;11(6):545-57
pubmed: 27513102
J Immunol. 1987 Jun 15;138(12):4114-20
pubmed: 2884260
JAMA. 1986 Dec 12;256(22):3110-6
pubmed: 3023712
Br J Dermatol. 1985 Jun;112(6):647-53
pubmed: 3890921
J Invest Dermatol. 1993 Nov;101(5):701-5
pubmed: 7693825
J Clin Invest. 1996 Oct 15;98(8):1878-87
pubmed: 8878440
Lancet. 1997 Aug 2;350(9074):349-53
pubmed: 9251649

Auteurs

Isabelle Lorthois (I)

Centre de recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada. isabelle.lorthois.1@ulaval.ca.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada. isabelle.lorthois.1@ulaval.ca.

Mélissa Simard (M)

Centre de recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada. melissa.simard.6@ulaval.ca.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada. melissa.simard.6@ulaval.ca.

Sophie Morin (S)

Centre de recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada. sophie.morin.7@ulaval.ca.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada. sophie.morin.7@ulaval.ca.

Roxane Pouliot (R)

Centre de recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec, Université Laval, Québec, QC G1J 1Z4, Canada. roxane.pouliot@pha.ulaval.ca.
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada. roxane.pouliot@pha.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH